Please login to the form below
Sutimlimab
This page shows the latest Sutimlimab news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
Sutimlimab – a first-in-class selective inhibitor of complement C1s – has hit the mark in cold agglutinin disease (CAD), a rare, autoimmune form of haemolytic anaemia that causes blood clots, leading ... In the phase 3 CARDINAL study reported at the
Latest news
-
Sanofi exits R&D pact with Alnylam on rare disease
The French drugmaker is also working on sutimlimab, an antibody for cold agglutinin disease in phase 3 testing, long-acting clotting factor BIVV001 for haemophilia A (phase 2) and gene-editing
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- FDA hands BMS and bluebird bio a priority review for ide-cel
- 20 for 2020 – Five pharma companies to watch
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
